

# Oregon Prescription Drug Monitoring Program 2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020


[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



## Summary

- Integrated queries have increased 1,039.4% while web queries have decreased by 29.5% from the 2nd quarter of 2020 (Table 1).
- Prescriptions for amphetamine (+ 19.2 %) and methylphenidate (+ 12.6 %) have increased the most since 2020 Q2 relative to the rest of the most commonly prescribed controlled substances (Table 5).
- Registration has increased for all user disciplines, but especially for NDs (+ 145%).
- Percent changes included in this report should be interpreted with caution since the comparison quarter (2020 Q2) was during the beginning of the COVID-19 pandemic in the United States, where many aspects of medical care were different.
- 22.8% of opioid prescribers this quarter were responsible for at least one prescription of over 90 morphine milligram equivalents (calculated as 23.8% for the first time in 2021 Q1).#

Oregon PDMP Registration: 2013-2021



† Query data drawn from Appriss AWAxR and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

# Revised on 2021-12-14 from an earlier report.

Oregon Prescription Drug Monitoring Program  
2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Table 1. PDMP Queries Summary Statistics: April-June, 2021

Measure	Web Portal	% Change*	Integrated	% Change*
Queries †	206,242	- 29.5 %	7,670,043	+ 1,039.4 %
Healthcare providers	58,219	- 23.7 %	6,649,013	+ 1,088.7 %
Pharmacies	39,844	- 43.3 %	1,021,030	+ 797.2 %
Delegates	108,072	- 26.0 %	-	-

- Web Portal queries have decreased from the same quarter last year across all user groups.
- The number of integrated queries continues to increase.
- Percent changes of integrated queries may be especially large because queries were low during COVID-19 lockdowns in 2020 Q2.
- Patterns of PDMP use are likely driven by the increasing adoption of PDMP integration by hospitals, clinics and pharmacies.

Table 2. Special Requests: April-June, 2021

Measure	Count
Special Requests Total	95
Patient Records	17
Healthcare Board	68
Law Enforcement	10

- 95 special requests were received and processed by PDMP staff.
- Healthcare boards were the most frequent originators of these requests.
- Request numbers appear to have rebounded after decreases seen during the COVID-19 pandemic.

\* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWAxR web portal, the PMPi Gateway audit file and the EDIE supplementary audit file. Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

# Oregon Prescription Drug Monitoring Program 2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

[healthoregon.org/pdmp](http://healthoregon.org/pdmp)



**Table 3. PDMP Enrollment and System Use: April-June, 2021**

	Prescribers	Enrolled	Web Queried	Integrated	Total Queried
<b>All Prescribers</b>	18,344	15,627 / 85.2 %	3,954 / 25.3 %	10,713 / 68.6 %	11,686 / 74.8 %
<b>Top 4K Prescribers</b>	4,000	3,866 / 96.7 %	1,796 / 46.5 %	3,311 / 85.6 %	3,540 / 91.6 %
<b>Top 2K Prescribers</b>	2,000	1,955 / 97.8 %	1,036 / 53 %	1,700 / 87 %	1,820 / 93.1 %

- During the 2nd quarter of 2021 there were 18,344 prescribers who wrote prescriptions for controlled substances in Oregon.
- At the close of the 2nd quarter, 74.8 % of enrolled prescribers queried the system; 91.6 % of the top 4,000 prescribers; 93.1 % of the top 2,000 prescribers through the web portal or integration.
- The percentage of enrolled prescribers who queried the system is much higher than the second quarter of 2020, when only 48.4% queried the system. This may have occurred due to a reduced number of appointments related to the COVID-19 pandemic.

**Table 4. PDMP Query by Clinical User Group: April-June, 2021**

Discipline	Total User Accounts	% Change*	Web Users <sup>±†</sup>	% Change*	Integrated Users	% Change*
MD/PA/DO	18,797	+ 10.1 %	1,571	- 16.3 %	12,943	- 23.1 %
NP/CNS-PP	5,012	+ 26.1 %	859	- 8.7 %	3,027	+ 262.9 %
RPh	4,141	+ 10.2 %	1,267	- 20.1 %	352	- 49.2%
Delegates	3,800	+ 13.4 %	1,746	- 14.5 %	-	-
DDS/DMD	3,612	+ 26.6 %	343	- 9.5 %	252	+ 460.0 %
ND	1,446	+ 145.9 %	128	- 17.9 %	433	+ 1,212.1 %

- Patterns of registration are likely driven by state mandated PDMP registration for prescribers and HIT integration efforts undertaken by health care systems.
- The number of users accessing the PDMP through the web portal is decreasing, while integrated users are increasing.
- Percent change in query numbers may be especially high due to low querying in the comparison quarter that was associated with changes in medical practices due to COVID-19.

\* Percentage change figures evaluated relative to the same time period during the prior year.

<sup>±</sup> Users that have submitted a query this quarter.

<sup>†</sup> Query data drawn from Appriss AWA<sup>®</sup> and PMPi Gateway.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program  
2021 2nd Quarter Report

Percentage change evaluated relative to 2nd Quarter, 2020

healthoregon.org/pdmp



Table 5. Top Prescriptions: April-June, 2021

Drug	# of Rx	% of all Rx	% Change*
All	1,689,233	100.0 %	+ 7.0 %
Hydrocodone	244,258	15.5 %	+ 5.3 %
Oxycodone	231,275	13.7 %	+ 13.3 %
Gabapentin	227,416	13.5 %	+ 4.6 %
Amphetamine	169,004	10 %	+ 19.2 %
Lorazepam	82,771	4.9 %	+ 2.7 %
Tramadol	82,748	4.9 %	+ 1.0 %
Methylphenidate	74,133	4.4 %	+ 12.6 %
Zolpidem	65,873	3.9 %	-3.9 %
Alprazolam	60,615	3.6 %	-1.9 %
Clonazepam	59,726	3.5 %	-3.2 %

- Prescriptions for stimulants (i.e., amphetamine, methylphenidate) increased relative to the same quarter last year.
- Oxycodone and hydrocodone prescriptions increased.
- The number of prescriptions for some commonly prescribed benzodiazepines decreased (i.e., alprazolam, clonazepam), but not for lorazepam (+ 2.7 %).
- Prescriptions for gabapentin increased, reflecting compliance with the addition of this drug as a PDMP covered substance, effective January 1st, 2020. This addition also contributed to an overall increase in the number of prescriptions in the PDMP.

Table 6. Prescriptions for Buprenorphine and Naloxone: April-June, 2021

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine	21,995	1.3 %	- 40.0 %
Buprenorphine/Naloxone	10,326	0.6 %	- 56.3 %
Naloxone	5,859	0.3 %	+ 38.6 %

- Prescriptions for naloxone have increased while prescriptions for buprenorphine and buprenorphine/naloxone combinations have decreased relative to the same quarter last year.

Contact: PDMP Research Analyst, [pdmp.research@state.or.us](mailto:pdmp.research@state.or.us)

\* Percentage change figures evaluated relative to the same time period during the prior year